RLAY stock forecast, quote, news & analysis

Key Takeaways

• Relay Therapeutics (RLAY) surged approximately 26% over the past 30 days, climbing from around $14.81 on June 12 to $18.73 as of July 13, 2026, driven by a series of compelling clinical data readouts and analyst upgrades.
• The stock's rally was propelled by positive Phase 2 data for zovegalisib in vascular anomalies showing a 60% volumetric response rate, far exceeding the 11%–20% historical benchmark.
• Multiple Wall Street analysts raised price targets, with JPMorgan initiating coverage at Overweight and a $28 target, while HC Wainwright, Barclays, Raymond James, and Guggenheim also lifted estimates.
• The company's addition to multiple Russell growth indexes in late June broadened institutional visibility and attracted passive fund inflows.
• Insider selling by the CFO and CEO generated some headlines but appeared tied to pre-scheduled Rule 10b5-1 trading plans rather than a shift in management sentiment.
• Relay's pipeline momentum across breast cancer and vascular anomalies has solidified its position as a leading precision oncology developer in the PI3Kα inhibitor space.

Relay Therapeutics (RLAY) Company Overview and Market Position

Relay Therapeutics is a clinical-stage precision medicine company headquartered in Cambridge, Massachusetts, focused on developing small molecule therapies for cancer and genetic diseases. The company's proprietary Dynamo® platform integrates advanced computational modeling, structural biology, and experimental validation to drug protein targets that have historically proven intractable. Relay's lead product candidate, zovegalisib (RLY-2608), is a first-in-class allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor currently in clinical development for HR+/HER2- metastatic breast cancer and PIK3CA-driven vascular anomalies. The company also advances RLY-8161, an NRAS-selective inhibitor, and preclinical programs including a non-inhibitory chaperone for Fabry disease. With a market capitalization of approximately $4.1 billion and strong institutional ownership exceeding 96%, Relay has attracted significant investor attention as its pipeline matures toward pivotal trials and potential regulatory filings.

Relay Therapeutics (RLAY) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 calendar days, Relay Therapeutics shares delivered a powerful rally, gaining roughly 26% from a closing price of $14.81 on June 12, 2026, to $18.73 on July 13, 2026. The stock reached an intra-quarter high of $20.79 on July 9 before a modest pullback in the most recent sessions. Volume patterns confirmed institutional participation, with several trading days recording above-average activity coinciding with key analyst initiations and clinical conference presentations.

The quarterly trend has been equally impressive, with RLAY more than doubling from levels seen earlier in the spring. The broader upward trajectory reflects an accumulation of positive catalysts: Breakthrough Therapy designation from the FDA in February, updated interim clinical data in March showing an 11-month median progression-free survival (PFS) in second-line breast cancer, and the late-May vascular anomalies data that significantly de-risked the pipeline. A $275 million public offering priced at $12.00 per share in May strengthened the balance sheet while the stock continued appreciating, indicating strong investor demand absorbing the dilution without derailing momentum.

What Drove RLAY Stock Price in the Last 30 Days

The most significant catalyst during the past 30 days was the sustained digestion of Relay's vascular anomalies data originally presented in May and further discussed at the ISSVA conference in Philadelphia. The Phase 2 ReInspire trial showed zovegalisib achieving a 60% volumetric response rate at 12 weeks across doses, with 89% of investigators and 79% of patients reporting clinical improvement. These results dramatically exceeded the 11%–20% benchmark set by existing therapies and expanded the addressable market narrative for zovegalisib beyond oncology into a multi-billion-dollar rare disease opportunity.

Wall Street responded forcefully. On July 8, JPMorgan initiated coverage with an Overweight rating and a $28 price target, characterizing zovegalisib as "a credible multi-indication growth driver." This followed a wave of target increases from HC Wainwright ($28), Barclays ($27), Raymond James ($26), and Guggenheim ($26), all citing confidence in the upcoming Phase 3 ReDiscover-2 trial in breast cancer. JonesResearch upgraded the stock from Hold to Buy in late May.

Additional tailwinds included Relay's addition to several Russell growth indexes — including the Russell 3000 Growth, Russell 2000 Growth, and Russell 2500 Growth — at the end of June, mechanically increasing demand from index-tracking funds. Conference presentations at Goldman Sachs and Jefferies healthcare events reinforced the management team's articulation of a clear path toward accelerated approval in vascular anomalies and eventual commercialization. Insider sales by CFO Thomas Catinazzo ($3.18 million) and CEO Sanjiv Patel ($943,000) briefly surfaced in financial media but were executed under pre-established 10b5-1 trading plans and did not diminish bullish sentiment.

What Drove RLAY Stock Performance Over the Last Quarter

The quarterly rally was built on multiple layers of clinical validation. In February 2026, the FDA granted Breakthrough Therapy designation to zovegalisib plus fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer, signaling regulatory acknowledgment of the drug's differentiated profile. In March, interim data from the ReDiscover trial at the 400mg BID fed dose — the Phase 3 dose — demonstrated an 11-month PFS that nearly doubled the 5.5-month benchmark established by AZN's capivasertib.

In May, the vascular anomalies data fundamentally reset the investment narrative. The 60% volumetric response rate, combined with a clean safety profile and high rates of symptomatic improvement, opened a pathway into an estimated $6–8 billion U.S. market with no satisfactory treatment options. The $275 million public offering that followed — upsized from $175 million due to strong demand — eliminated near-term financing overhang while shares continued to appreciate, a rare signal of conviction in the biotech sector. Throughout June, the company's active presence at major medical and investor conferences kept the story in focus, and the Russell index inclusion at quarter-end provided a structural boost as passive funds adjusted their portfolios.

Trending AI Robots

For investors seeking data-driven approaches to navigate volatile biotechnology markets, Tickeron's Trending AI Robots page offers a curated selection of top-performing algorithmic trading bots. Tickeron's platform hosts hundreds of AI-powered trading bots covering thousands of tickers across diverse sectors and strategies, but only those demonstrating consistent, verifiable performance metrics earn placement in the trending section. These bots span multiple timeframes — from intraday swing trading to longer-duration position strategies — and incorporate technical, fundamental, and sentiment-based signals tailored to each stock's unique behavior. Exploring the trending section can help traders identify opportunities aligned with their risk tolerance and investment style.

RLAY Stock Forecast Drivers: What Investors Should Watch Next

The primary near-term catalyst is the continued enrollment and eventual data readout from the Phase 3 ReDiscover-2 trial evaluating zovegalisib plus fulvestrant versus capivasertib plus fulvestrant in second-line HR+/HER2- breast cancer. Management has indicated enrollment is progressing well, with guidance on full enrollment expected later in 2026. Any interim efficacy or safety signals will be closely scrutinized. Additionally, investors should monitor progress toward an accelerated approval filing in vascular anomalies given the strength of the ReInspire data and ongoing FDA engagement.

The upcoming earnings report, expected around August 6, 2026, will provide updates on cash runway, R&D expenditure trends, and strategic priorities. With approximately $550 million in cash at year-end 2025 plus the May 2026 offering proceeds, Relay is well-capitalized, but continued clinical investment means cash burn remains a factor. Macroeconomic considerations — including interest rate policy and sector rotation dynamics — will affect risk appetite for pre-revenue biotech names. Competitive developments in the PI3Kα and CDK4/6 inhibitor landscape, as well as any regulatory updates from the FDA on accelerated approval pathways, will also influence sentiment around RLAY.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.